Friday, February 10, 2012

Endoscopy Doesn't Have to Be Unsightly

Capsule Endoscopy can conjure up a negative image for patients; the leads and wires attached to their torso leading to a recording device that is worn on a belt or harness. This is needed in current systems due to the wireless technology used in transmitting the pictures captured by the capsule endoscope through radio-frequency signals.

Some products are looking to get the process down to no more than taking a pill. One such product, available for sale in the UK, France, Germany, and India, is Capsovision's Capsocam SV-1. The unit features a tiny, 360 degree camera available for sale in Europe and India through medical distributors. Pictures are downloaded, rather than transmitted by radio.

"The patient doesn't need to look like a bomber with a datarecorder and sensor attached to them anymore," says Tim O'Dwyer, Capsule Endoscopy Specialist for hte Saratoga, CA-based company. He recently spoke with Kalorama Information.

According to O'Dwyer, the new capsule Capsocam SV-1 has four cameras and 15hours of
battery operating time minimum and can take more pictures than the average unit.

"That's over half a million photographs compared to less than 80,000 taken by the market leader," O'Dwyer said.

Another system by Sayaka Corp uses an inner lens that constantly rotates so that a 3D image of the canal is taken. Sayaka's Capsule has a lens on the lateral surface of the capsule instead of the front. This new design obtains clear-cut lateral images of the gastrointestinal wall while the inner capsule spins in the digestive tract. The unit is battery free.

Capsule Endoscopy is one of the faster growing market segments in GI and more competitors are expected. We've completed a whole market research study on this promising area. Kalorama Information's latest report can be found on our website:Gastrointestinal Devices market research report.

Wednesday, February 8, 2012

Cancer Biotherapy Revenues Settle Down, But Still Strong

In the last decade, one of the most promising new approaches in modern cancer treatment is immunotherapy or biotherapy, the development of methods to augment and enhance the body’s natural tendency to defend itself against malignant tumors without damaging healthy tissue. Therapies such as monoclonals or interleukins were growing at over 25% between 2005 and 2010.

That type of revenue growth could not have been sustained forever. As these products become an increasingly common part of treatment, we note that growth rates - while still very high - have slowed from previous levels. Kalorama notes in Cancer Therapeutics , our latest study, that biotherapies grew at 10% between 2010 and 2011. That new revenue growth rate though should hold long-term, at least the next five years, and still makes for a very comfortable atmosphere for new product introductions.

Cancer is the second most common cause of death in the industrialized world. Most cancer patients are treated with some combination of surgery, radiation, and chemotherapy. Unfortunately, radiation and chemotherapy destroy healthy as well as malignant cells and thus can cause severe side effects.

The rising incidence of cancer, particularly in the over 50 population, is likely have a significant impact on all areas of cancer treatment. However, for many cancer types, there remains a significant unmet need in effective treatment. Lung cancer is one example as patient survival is less than five years after diagnosis. Traditional therapies have failed to provide adequate treatment for these patients, signifying a need for an alternative treatment plan. Compassionate use has been granted for several therapies in the past and this trend is likely to continue.

Monday, February 6, 2012

Canada Moves Highlights Interest in Personalized Medicine

A challenge to anyone promoting a therapeutic or a medical device in healthcare markets currently is that no matter how good it is, even if it is better than current regimens, payors both in the U.S. and Europe are seeking to cut costs, and that usually doesn't present a good market for innovative but more expensive solutions. This austerity is lead by governments, and is echoed by private payors.

Most major governments have undergone some type of cost-cutting program. In the U.S., while healthcare reform will likely expand the insured population, it also can be considered at least partially a 'cost-cutting' program that features payment decreases to providers and fees on devices.

It's possible that tests may be different, particularly those molecular tests that can improve patient outcomes and lessen the use of a therapeutic in a case where it has little probability of working. Canada's recent move to provide millions for personalized medicine products highlights how even in an austerity time, a product that can cut costs long-term has promise.

Kalorama has always discussed personalized medicine in its IVD reports, but we have recently completed our first full market research study on the concept. Personalized Medicine Diagnostics is available for pre-publication orders now and will publish on March 1st, 2012.

Wednesday, February 1, 2012

Will New Hep C Combo Drugs Change Treatment Scenario?

Last year saw the approval of Merck's Victrelis (boceprevir) drug and J&J's Incivek, (telaprevir), protease inhibitors which, along with other pharmaceuticals, enhance the attack on the Hepatitis C (HCV) virus. In 2012 we may see the market effects. It's possible the drugs may change what was previously a very dreary treatment scenario for this serious condition.

Hepatitis C affects both men and women. It is the leading cause of acute liver inflammation and liver cancer and the most common cause of needing a liver transplant. More than 170 million people worldwide are infected, while 3-4 million people are diagnosed each year. In the United States, approximately 4 million are living with this disease, while in Europe and Japan another 4 million and 2 million are living with the disease, respectively.

Used in combinations, the new drugs showed in clinical trials that they can succeed at as high as a 70% response rate, about 30% higher than the therapies on the market. Diagnostic companies should be interested in this development: there's now a realistic treatment, thus more tests may be needed.

Kalorama breaks out the market opportunity for pharmaceuticals treating infection by infection type (including HCV and HIV) in a new study on the subject:
http://www.kaloramainformation.com/Anti-Infectives-Antifungals-6772957/

Monday, January 30, 2012

Interview with Illumina CEO Flatley Points to Clinical Sequencing

Lest anyone wonder why Illumina is a target for a very persistent Roche, and why they in turn are adopting strong defensive measures, it's important to consider the role of sequencing in clinical diagnostics, especially in cancer applications. Washington Post.com video interview with Illumina CEO Jay Flatley points to the company's vision of a future in clinical applications for sequencing. If you've sequenced a tumor, you've got a 'much better roadmap" to treatment.

It's likely that payors would agree, given the drop in costs. With sequencing costs expected to get down to one thousand dollars, it's not hard to imagine that a DNA sequencing of a tumor will be seen as a reasonable investment for care of a patient if the outcome can be improved at all by a sequencing, and if it can better target the therapeutic steps. It's therefore not a business that a major marketer of IVD can ignore.

Wednesday, January 25, 2012

Roche / Illumina Take Over - How Will It Affect Sequencer Market?

There is a high value on companies that touch on personalized medicine, and that is driving the news today of Roche making a hostile takeover attempt of Illumina Roche highly values the technology to do sequencing in order to add to its research and clinical diagnostics offerings.

Most of the speculation (and probably warranted) as to the reasons for the attempt have to do with future capabilities with companion diagnostics products and new molecular testing tools. This adds extra value to Illumina for Roche. There is a present market as well for sales of the equipment for research lab sales, and any takeover would affect that market as well.

In labs around the world, Illumina sequencers compete with Roche's 454 next-generation system, as we reported on extensively in our report DNA Sequencing Trends, which surveyed sequencing lab managers and users. Illumina systems were a key target for future buyers. An open question would be what Roche does with its 454 line if the takeover is completed.

Tuesday, January 24, 2012

A Better Year for Retail Clinics

Retail Clinics had an easier go of it in 2011 than in the struggling years of 2010 and 2009, where the very concept was under attack. The number of clinics is increasing, as the firm Merchant Medicine indicates: According to the report as quoted in the New York Times.
The number of retail clinics jumped 11.2 percent to 1,355 in 2011 after slow growth in 2010 and 2009, according to a report by Thomas Charland, chief executive of Merchant Medicine, which tracks the growth of retail medical care services. The number of retail clinics rose only 3 percent in 2010 and had flat growth in 2009 when the financial crisis and the related poor real estate market caused some smaller operators to close their doors. This followed several years of rapid growth.

The potential for clinics is far from tapped. Even 1,300 stores, given the retail universe of the United States, is a small amount. In Kalorama's analysis on this topic, we've indicated that the retail clinic concept proved not to be recession-proof, and that it failed to expand much beyond the drug store arena. But in that arena it is succeeding well, and corporate decisions at major chains could lead to giant increases in this market.

Kalorama has been covering retail clinics since 2007. Our report on the subject which includes not only store growth forecasts but also business projections for retail clinics and supplier selling to retail clinics can be found at the Kalorama Information website. This is an industry which many see as benefiting from healthcare reform as it offers newly insured who may not have an existing provider a convenient option for care.